目前， 河南省肿瘤医院血液科淋巴瘤病区 有9项淋巴瘤临床研究正在进行，有需要的患者朋友欢迎电话咨询详情。 一项研究 “抗CD19/CD20嵌合抗原受体自体T细胞注射液（C-CAR039）治疗CD19或CD20阳性的复发或难治性大B细胞淋巴瘤的Ib/II期临床研究” （CTR编号 CTR20222827）。该研究已经通过医院伦理委员会的审查（CTMS编号 2023-477）。

目前，河南省肿瘤医院血液科淋巴瘤病区有9项淋巴瘤临床研究正在进行，有需要的患者朋友欢迎电话咨询详情。01一项研究“抗CD19/CD20嵌合抗原受体自体T细胞注射液（C-CAR039）治疗CD19或CD20阳性的复发或难治性大B细胞淋巴瘤的Ib/II期临床研究”（CTR编号 CTR20222827）。该研究已经通过我院伦理委员会的审查（CTMS编号 ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

Figure 1: Transgene expression and phenotype. Figure 2: K14.MYC2 mice exhibit impairment in wound healing. Figure 3: K14.MYC2 primary keratinocytes exhibit a defect in migration. Figure 4: K14 ...

Here, we review the ongoing developments with CAR T cells in the field of autoimmune disorders. We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T ...